Stratmann H G, Younis L T, Wittry M D, Amato M, Miller D D
Department of Internal Medicine, St. Louis Veterans Administration Medical Center, MO 63106, USA.
Am Heart J. 1996 May;131(5):923-9. doi: 10.1016/s0002-8703(96)90174-x.
Dipyridamole thallium-201 myocardial imaging can provide information regarding risk of perioperative cardiac events in patients being considered for vascular surgery. The value for this purpose of myocardial imaging with technetium-99m sestamibi (MIBI), a radiotracer with biokinetic and imaging properties different from thallium-201, has not been established. To this end the prognostic value of dipyridamole MIBI tomography for perioperative and late cardiac events was evaluated in 229 consecutive patients being considered for elective vascular surgery. Vascular surgery was done < or = 3 months after testing in 197 of these patients. Perioperative cardiac events (cardiac death, nonfatal myocardial infarction, unstable angina, or ischemic pulmonary edema) occurred in 9 (5%) patients. The rate of such events was 3% in patients with normal MIBI results, 5% in those with abnormal results, and 6% in patients with a reversible MIBI defect (both p = NS). When patients with abnormal MIBI results who had preoperative cardiac interventions (coronary revascularization or an increase in antiischemic medical therapy) were compared with with those who did not, no significant differences in the occurrence of perioperative cardiac events were found between these two groups either. A group of 172 medically treated patients who survived vascular surgery and did not have a nonfatal perioperative cardiac event was then monitored (mean 21 +/- 14 months) for the occurrence of a serious late cardiac event (nonfatal myocardial infarction or cardiac death). Event-free survival (Mantel-Cox) was significantly less in patients with abnormal studies compared with those with normal scan results. Late cardiac events occurred in 26 (15%) patients, with those having an abnormal MIBI result showing a significantly greater event rate than those with normal results (26% vs 4%, p < 0.0001). The rate of late cardiac events was 33% in patients with a reversible MIBI defect (p < 0.001) and 23% in those with a fixed defect (p < 0.03). Independent Cox multivariable predictors of increased risk of late cardiac events were a history of diabetes mellitus (relative risk [RR] 2.2, 95% confidence interval [CI] 1.0 to 4.9), an abnormal MIBI study (RR 3.7, 95% CI 1.2 to 11.4), and a reversible MIBI defect (RR 2.7, 95% CI 1.2 to 6.1). We conclude that, although its ability to assess increased perioperative cardiac risk remains uncertain, dipyridamole MIBI tomography does provide important prognostic information regarding the risk of serious cardiac events in patients having vascular surgery. The presence of an abnormal MIBI result, specifically one demonstrating a reversible perfusion defect, is associated with significantly increased risk.
双嘧达莫 - 铊 - 201心肌显像可为拟行血管手术患者围手术期心脏事件的风险提供相关信息。锝 - 99m甲氧基异丁基异腈(MIBI)心肌显像作为一种生物动力学和显像特性与铊 - 201不同的放射性示踪剂,其在此方面的价值尚未明确。为此,我们对229例拟行择期血管手术的连续患者评估了双嘧达莫MIBI断层扫描对围手术期及晚期心脏事件的预后价值。其中197例患者在检查后≤3个月接受了血管手术。9例(5%)患者发生围手术期心脏事件(心源性死亡、非致死性心肌梗死、不稳定型心绞痛或缺血性肺水肿)。MIBI结果正常的患者此类事件发生率为3%,结果异常的患者为5%,有可逆性MIBI缺损的患者为6%(均P = 无显著性差异)。将术前接受心脏干预(冠状动脉血运重建或抗缺血药物治疗增加)的MIBI结果异常患者与未接受干预的患者进行比较,两组围手术期心脏事件发生率也无显著差异。随后对172例接受药物治疗、血管手术存活且未发生非致死性围手术期心脏事件的患者进行了监测(平均21±14个月),观察严重晚期心脏事件(非致死性心肌梗死或心源性死亡)的发生情况。与扫描结果正常的患者相比,检查异常的患者无事件生存率(Mantel - Cox法)显著降低。26例(15%)患者发生晚期心脏事件,MIBI结果异常的患者事件发生率显著高于结果正常的患者(26%对4%,P < 0.0001)。有可逆性MIBI缺损的患者晚期心脏事件发生率为33%(P < 0.001),有固定缺损的患者为23%(P < 0.03)。晚期心脏事件风险增加的独立Cox多变量预测因素包括糖尿病史(相对风险[RR] 2.2,95%置信区间[CI] 1.0至4.9)、MIBI检查异常(RR 3.7,95% CI 1.2至11.4)以及可逆性MIBI缺损(RR 2.7,95% CI 1.2至6.1)。我们得出结论,虽然双嘧达莫MIBI断层扫描评估围手术期心脏风险增加的能力仍不确定,但它确实为行血管手术患者严重心脏事件的风险提供了重要的预后信息。MIBI结果异常,特别是显示可逆性灌注缺损,与风险显著增加相关。